Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01165632 · ClinicalTrials.gov registry record · Early Phase 1

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

A Early Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Early Phase 1
Development phase
24
Enrollment target

NCT01165632: Completed Early Phase 1 study, sponsored by Mayo Clinic.

NCT01165632 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01165632, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target

Study Summary

RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma

Primary Outcome

Determine correlation between 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies.

Interventions

  • PROCEDURE biopsy
  • PROCEDURE therapeutic conventional surgery
  • PROCEDURE computed tomography
  • RADIATION radiation therapy
  • RADIATION radiation therapy treatment planning/simulation

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-07-26
Est. Completion 2019-07-26
Phase Early Phase 1
Mayo Clinic

2,844 total trials

What the finished NCT01165632 record still lists

NCT01165632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 5 interventions - of which biopsy is the first listed.

NCT01165632 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01165632 about?

NCT01165632 is a clinical study titled "Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma". RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therap...

What is the current status of trial NCT01165632?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2010-07-26. Estimated completion is 2019-07-26.

What interventions are being tested in trial NCT01165632?

The interventions under investigation include: biopsy (PROCEDURE), therapeutic conventional surgery (PROCEDURE), computed tomography (PROCEDURE), radiation therapy (RADIATION), radiation therapy treatment planning/simulation (RADIATION).

Who is sponsoring clinical trial NCT01165632?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01165632's enrollment target sits among peer trials

24 1037th of 2000 higher than 914 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01165632, the US trial registry maintained by the National Library of Medicine. NCT01165632 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.